Lignocaine Toxicity in Burn Cases
Esculapio · 10.08.2023 · 10 (4) · 198-200
DOI: 10.51273/esc14.7104-cr ↗Kurz gefasst
Fachartikel in der Zeitschrift Esculapio, online erschienen am 10.08.2023. Verfasst von Muhammad Asim und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Pain is one of the constant features of burn injuries. Many protocols are utilized to alleviate pain in these patients. Lignocaine containing ointment and fusidic acid in combination with hydrocortisone cream are routinely used as topical application in the wound care of burn patients at our setup. During a period of nine years, five patients experienced adverse effects of lignocaine, active ingredient of Ointment, which were immediately controlled once this drug was discontinued. All these patients, who were being treated for burn injury involving more than 20% BSA(Body Surface Area), responded well on excluding the lignocaine from treatment medication and did not require any anticonvulsant to treat these adverse effects.
Zitieren
APA
Asim, M., & Cheema, S. A. (2023). Lignocaine Toxicity in Burn Cases. Esculapio, 10(4), 198-200. https://doi.org/10.51273/esc14.7104-cr
Vancouver
Asim M, Cheema SA. Lignocaine Toxicity in Burn Cases. Esculapio. 2023;10(4):198-200. doi:10.51273/esc14.7104-cr
BibTeX
@article{Asim2023,
author = {Asim, Muhammad and Cheema, Saeed Ashraf},
title = {Lignocaine Toxicity in Burn Cases},
journal = {Esculapio},
year = {2023},
volume = {10},
number = {4},
pages = {198--200},
doi = {10.51273/esc14.7104-cr}
}
EUVIMED